Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Affirm Holdings, Inc. stock logo
AFRM
Affirm
$35.75
-8.1%
$58.49
$22.25
$82.53
$11.37B3.638.17 million shs18.88 million shs
ARCH
Arch Biopartners
$134.83
$0.00
$116.44
$180.65
N/AN/A359,920 shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$25.11
-2.4%
$33.55
$23.76
$170.47
$9.71B2.237.03 million shs16.04 million shs
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-8.12%-22.62%-39.05%-46.24%+6.21%
ARCH
Arch Biopartners
0.00%+13,482,999,900.00%+13,482,999,900.00%+13,482,999,900.00%+13,482,999,900.00%
Moderna, Inc. stock logo
MRNA
Moderna
-2.41%-19.31%-28.69%-40.47%-75.19%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Affirm Holdings, Inc. stock logo
AFRM
Affirm
3.1775 of 5 stars
4.32.00.00.02.33.30.6
ARCH
Arch Biopartners
N/AN/AN/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
4.2214 of 5 stars
4.01.00.04.62.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Affirm Holdings, Inc. stock logo
AFRM
Affirm
2.67
Moderate Buy$69.7695.15% Upside
ARCH
Arch Biopartners
0.00
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.00134.97% Upside

Current Analyst Ratings Breakdown

Latest ARCH, MRNA, and AFRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/24/2025
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Seaport Res Ptn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/20/2025
Affirm Holdings, Inc. stock logo
AFRM
Affirm
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$69.00
3/19/2025
Affirm Holdings, Inc. stock logo
AFRM
Affirm
Compass Point
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$61.00 ➝ $64.00
3/18/2025
Affirm Holdings, Inc. stock logo
AFRM
Affirm
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $56.00
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Affirm Holdings, Inc. stock logo
AFRM
Affirm
$2.80B4.06N/AN/A$8.78 per share4.07
ARCH
Arch Biopartners
N/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.03N/AN/A$28.33 per share0.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-$517.76M-$0.65N/A57.66N/A-7.10%-7.25%-2.02%5/8/2025 (Estimated)
ARCH
Arch Biopartners
N/AN/A0.00N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)

Latest ARCH, MRNA, and AFRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.90N/AN/AN/A$130.35 millionN/A
2/6/2025Q2 2025
Affirm Holdings, Inc. stock logo
AFRM
Affirm
-$0.21$0.23+$0.44$0.23$799.56 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Affirm Holdings, Inc. stock logo
AFRM
Affirm
N/AN/AN/AN/AN/A
ARCH
Arch Biopartners
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Affirm Holdings, Inc. stock logo
AFRM
Affirm
2.68
11.26
11.26
ARCH
Arch Biopartners
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62

Institutional Ownership

CompanyInstitutional Ownership
Affirm Holdings, Inc. stock logo
AFRM
Affirm
69.29%
ARCH
Arch Biopartners
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Affirm Holdings, Inc. stock logo
AFRM
Affirm
12.41%
ARCH
Arch Biopartners
N/A
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Affirm Holdings, Inc. stock logo
AFRM
Affirm
2,550318.06 million278.59 millionOptionable
ARCH
Arch Biopartners
N/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable

Recent News About These Companies

Moderna (MRNA) Gets a Hold from Bernstein
Is Moderna, Inc. (MRNA) the Best Gene-Editing Stock to Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Affirm stock logo

Affirm NASDAQ:AFRM

$35.75 -3.16 (-8.12%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$35.45 -0.30 (-0.84%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce in the United States, Canada, and internationally. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its commerce platform, agreements with originating banks, and capital markets partners enables consumers to pay for a purchase over time with terms ranging up to 60 months. The company has active merchants covering small businesses, large enterprises, direct-to-consumer brands, brick-and-mortar stores, and companies with an omni-channel presence. Its merchants represent a range of industries, including sporting goods and outdoors, furniture and homewares, travel and ticketing, apparel, accessories, consumer electronics, and jewelry. Affirm Holdings, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Arch Biopartners NYSE:ARCH

$134.83 0.00 (0.00%)
As of 01/14/2025

Moderna stock logo

Moderna NASDAQ:MRNA

$25.11 -0.62 (-2.41%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$24.92 -0.19 (-0.75%)
As of 04/4/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.